» Articles » PMID: 31185923

Validity of a Novel Screen for Cognitive Impairment and Neuropsychiatric Symptoms in Cardiac Rehabilitation

Overview
Journal BMC Geriatr
Publisher Biomed Central
Specialty Geriatrics
Date 2019 Jun 13
PMID 31185923
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Currently, there is no composite screening tool that can efficiently and effectively assess prevalent yet under-recognized cognitive and neuropsychiatric comorbidities in patients with cardiovascular disease. We aimed to determine the validity and feasibility of a novel screen assessing cognitive impairment, anxiety, apathy and depression (CAAD screen) in those attending cardiac rehabilitation (CR).

Methods: All patients diagnosed with cardiovascular disease or cardiovascular risk factors entering CR were screened as part of clinical care. A subset of those patients agreed to complete validation assessments (n = 127). Screen results were compared to widely accepted standards for cognition, anxiety, apathy, and depression using a modified receiver operating characteristic (ROC) and area under the curve analysis.

Results: The screen was completed by 97% of participants in 10 min or less with an average completion time of approximately 5 min. Screening scores adjusted for age, sex and years of education had acceptable or excellent validity compared to widely accepted standard diagnoses: CAAD-Cog (AUC = 0.80); CAAD-Anx (AUC = 0.81); CAAD-Apathy (AUC = 0.79) and CAAD-Dep (AUC = 0.85).

Conclusions: The CAAD screen may be a valid and feasible tool for detecting cognitive impairment, anxiety, apathy and depression in CR settings.

Citing Articles

PCSK9 Inhibition Reduces Depressive like Behavior in CUMS-Exposed Rats: Highlights on HMGB1/RAGE/TLR4 Pathway, NLRP3 Inflammasome Complex and IDO-1.

Hendawy N, Salaheldin T, Abuelezz S J Neuroimmune Pharmacol. 2023; 18(1-2):195-207.

PMID: 36781714 PMC: 10485135. DOI: 10.1007/s11481-023-10060-3.


Altered central and blood glutathione in Alzheimer's disease and mild cognitive impairment: a meta-analysis.

Chen J, Thiyagarajah M, Song J, Chen C, Herrmann N, Gallagher D Alzheimers Res Ther. 2022; 14(1):23.

PMID: 35123548 PMC: 8818133. DOI: 10.1186/s13195-022-00961-5.


Cognition and Exercise: GENERAL OVERVIEW AND IMPLICATIONS FOR CARDIAC REHABILITATION.

Gaalema D, Mahoney K, Ballon J J Cardiopulm Rehabil Prev. 2021; 41(6):400-406.

PMID: 34561368 PMC: 8563446. DOI: 10.1097/HCR.0000000000000644.


Developing a cognitive dysfunction risk score for use with opioid-dependent persons in drug treatment.

Copenhaver M, Sanborn V, Shrestha R, Mistler C, Sullivan M, Gunstad J Drug Alcohol Depend. 2021; 224:108726.

PMID: 33930640 PMC: 8180490. DOI: 10.1016/j.drugalcdep.2021.108726.

References
1.
Mandrekar J . Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010; 5(9):1315-6. DOI: 10.1097/JTO.0b013e3181ec173d. View

2.
Swartz R, Cayley M, Lanctot K, Murray B, Smith E, Sahlas D . Validating a Pragmatic Approach to Cognitive Screening in Stroke Prevention Clinics Using the Montreal Cognitive Assessment. Stroke. 2016; 47(3):807-13. DOI: 10.1161/STROKEAHA.115.011036. View

3.
Ambrose J, Singh M . Pathophysiology of coronary artery disease leading to acute coronary syndromes. F1000Prime Rep. 2015; 7:08. PMC: 4311268. DOI: 10.12703/P7-08. View

4.
Scott J . Pathophysiology and biochemistry of cardiovascular disease. Curr Opin Genet Dev. 2004; 14(3):271-9. DOI: 10.1016/j.gde.2004.04.012. View

5.
Eggermont L, de Boer K, Muller M, Jaschke A, Kamp O, Scherder E . Cardiac disease and cognitive impairment: a systematic review. Heart. 2012; 98(18):1334-40. DOI: 10.1136/heartjnl-2012-301682. View